| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Mohan Jitendra | Chief Executive Officer, Director | C/O ASTERA LABS, INC., 2345 NORTH FIRST STREET, SAN JOSE | /s/ Philip Mazzara, Attorney-in-Fact | 19 Mar 2026 | 0001998053 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALAB | Common Stock | Sale | $1,099,130 | -8,754 | -0.19% | $125.56 | 4,680,478 | 17 Mar 2026 | By Living Trust | F1, F2, F3 |
| transaction | ALAB | Common Stock | Sale | $727,699 | -5,746 | -0.12% | $126.64 | 4,674,732 | 17 Mar 2026 | By Living Trust | F1, F3, F4 |
| transaction | ALAB | Common Stock | Sale | $461,963 | -3,624 | -0.08% | $127.47 | 4,671,108 | 17 Mar 2026 | By Living Trust | F1, F3, F5 |
| transaction | ALAB | Common Stock | Sale | $1,017,168 | -7,907 | -0.17% | $128.64 | 4,663,201 | 17 Mar 2026 | By Living Trust | F1, F3, F6 |
| transaction | ALAB | Common Stock | Sale | $1,441,332 | -11,120 | -0.24% | $129.62 | 4,652,081 | 17 Mar 2026 | By Living Trust | F1, F3, F7 |
| transaction | ALAB | Common Stock | Sale | $1,814,685 | -13,880 | -0.3% | $130.74 | 4,638,201 | 17 Mar 2026 | By Living Trust | F1, F3, F8 |
| transaction | ALAB | Common Stock | Sale | $2,996,236 | -22,766 | -0.49% | $131.61 | 4,615,435 | 17 Mar 2026 | By Living Trust | F1, F3, F9 |
| transaction | ALAB | Common Stock | Sale | $5,745,377 | -43,289 | -0.94% | $132.72 | 4,572,146 | 17 Mar 2026 | By Living Trust | F1, F3, F10 |
| transaction | ALAB | Common Stock | Sale | $2,981,915 | -22,309 | -0.49% | $133.66 | 4,549,837 | 17 Mar 2026 | By Living Trust | F1, F3, F11 |
| transaction | ALAB | Common Stock | Sale | $2,438,269 | -18,105 | -0.4% | $134.67 | 4,531,732 | 17 Mar 2026 | By Living Trust | F1, F3, F12 |
| holding | ALAB | Common Stock | 699,999 | 17 Mar 2026 | By Trust | F13 | |||||
| holding | ALAB | Common Stock | 700,000 | 17 Mar 2026 | By 2021 Trust 1 | F14 | |||||
| holding | ALAB | Common Stock | 700,000 | 17 Mar 2026 | By 2021 Trust 2 | F15 | |||||
| holding | ALAB | Common Stock | 450,001 | 17 Mar 2026 | By 2022 Trust 1 | F16 | |||||
| holding | ALAB | Common Stock | 450,001 | 17 Mar 2026 | By 2022 Trust 2 | F17 | |||||
| holding | ALAB | Common Stock | 1,452,739 | 17 Mar 2026 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.0700 to $126.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.0800 to $127.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.1100 to $128.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.1500 to $129.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.1600 to $130.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.1600 to $131.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.1600 to $132.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.1750 to $133.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F11 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.1775 to $134.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F12 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.2000 to $135.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F13 | These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F14 | These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F15 | These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F16 | These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F17 | These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |